News

Stocktwits on MSN5h
Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms
JPMorgan cut its price target on Sage Therapeutics to $8.5 from $11 based on the recently announced buyout by Supernus ...